

12 February 2025

**Deltex Medical Group plc**  
("Deltex Medical" or the "Company")

**Result of General Meeting**

Deltex Medical Group plc (AIM: DEMG) announces that at the general meeting of the Company held earlier today, the Cancellation Resolution put to the Company's shareholders was duly passed. As a result, the Company's Ordinary Shares will be cancelled from trading on AIM at 7.00 a.m. on 21 February 2025. The proxy voting results are as follows:

	Total votes cast	Votes		Votes		Withheld*
		FOR		AGAINST		
	Votes	Votes	% of shares voted	Votes	% of shares voted	Votes
Cancellation Resolution	1,278,213,356	1,239,890,686	97.00%	38,322,670	3.00%	65,953

\*A "vote withheld" is not a vote in law and will not be counted in the calculation of the proportion of the votes for and against a resolution.

**Shareholders are reminded that the last day of dealings in the Company's Ordinary Shares on AIM will be 20 February 2025.**

**Dealing and settlement arrangements post the Cancellation**

With effect from Cancellation, the Company has arranged a Matched Bargain Facility and has appointed JP Jenkins (a trading name of InfinitX Limited and an appointed representative of Prosper Capital LLP, which is authorised and regulated by the FCA) to facilitate Shareholders buying and selling of Ordinary Shares on a matched bargain basis for a period of no less than 12 months following Cancellation. Full details will be made available to Shareholders on the Company's website at [www.deltexmedical.com](http://www.deltexmedical.com) and directly by letter or e-mail (where appropriate).

There can be no guarantee as to the level of the liquidity or marketability of the Ordinary Shares under the Matched Bargain Facility, or the level of difficulty for Shareholders seeking to realise their investment under the Matched Bargain Facility.

Further details of the Cancellation, including the full text of the Cancellation Resolution, can be found in the Circular which was published and sent to shareholders on 21 January 2025 and is available on the Company's website at [www.deltexmedical.com](http://www.deltexmedical.com).

**Capitalised terms used in this announcement shall have the meanings given to such terms in the announcement issued by the Company dated 21 January 2025 unless otherwise defined herein.**

**For further information, please contact:**

**Deltex Medical Group plc**  
Nigel Keen, Chairman  
Andy Mears, Chief Executive  
Natalie Wettler, Group Finance Director  
& Chief Operating Officer

01243 774 837  
[investorinfo@Deltexmedical.com](mailto:investorinfo@Deltexmedical.com)

**Allenby Capital Limited - Nominated Adviser & Broker**  
Jeremy Porter / Vivek Bhardwaj (Corporate Finance)  
Tony Quirke / Stefano Aquilino (Sales & Corporate Broking)

020 3328 5656  
[info@allenbycapital.com](mailto:info@allenbycapital.com)

## **Notes for Editors**

### **Deltex Medical's technology**

Deltex Medical's TrueVue System uses proprietary haemodynamic monitoring technology to assist clinicians to improve outcomes for patients as well as increase throughput and capacity for hospitals.

Deltex Medical has invested over the long term to build a unique body of peer-reviewed, published evidence from a substantial number of trials carried out around the world. These studies demonstrate statistically significant improvements in clinical outcomes providing benefits both to patients and to the hospital systems by increasing patient throughput and expanding hospital capacity.

The Group's flagship, world-leading, ultrasound-based oesophageal Doppler monitoring ("ODM") is supported by 24 randomised control trials conducted on anaesthetised patients. As a result, the primary application for ODM is focussed on guiding therapy for patients undergoing elective surgery, although sedated patients in intensive care are still an important part of our business. The Group's new, next generation monitor makes the use of the ODM technology more intuitive and provides augmented data on the status of each patient.

Deltex Medical's engineers and scientists carried out successful research in conjunction with the UK's National Physical Laboratory ("NPL"), which has enabled the Group's 'gold standard' ODM technology to be extended and developed so that it can be used completely non-invasively. This will significantly expand the application of Deltex Medical's technology to non-sedated patients. This new technological enhancement, which will be released on the new next generation monitor, will substantially increase the addressable market for the Group's haemodynamic monitoring technologies and is complementary to the long-established ODM evidence base.

Deltex Medical's new non-invasive technology has potential applications for use in a number of healthcare settings, including:

- Accident & Emergency for the rapid triage of patients, including the detection and diagnosis of sepsis;
- in general wards to help facilitate a real-time, data-driven treatment regime for patients whose condition might deteriorate rapidly; and
- in critical care units to allow regular monitoring of patients post-surgery who are no longer sedated or intubated.

One of the key opportunities for the Group is positioning this new, non-invasive technology for use throughout the hospital. Deltex Medical's haemodynamic monitoring technologies provide clinicians with beat-to-beat real-time information on a patient's circulating blood volume and heart function. This information is critical to enable clinicians to optimise both fluid and drug delivery to patients.

Deltex Medical's business model is to drive the recurring revenues associated with the sale of single-use disposable ODM probes which are used in the TrueVue System and to complement these revenues with a new incremental revenue stream to be derived from the Group's new non-invasive technology.

Both the existing single-use ODM probe and the new, non-invasive device will connect to the same, new TrueVue monitor which was released onto the market in November 2023. Monitors are sold or, due to hospitals' often protracted procurement times for capital items, may be loaned in order to encourage faster adoption of the Group's technology.

### **Deltex Medical's customers**

The principal users of Deltex Medical's products are currently anaesthetists working in a hospital's operating theatre and intensivists working in ICUs. This customer profile will change as the Group's new non-invasive technology is adopted by the market. In the UK the Group sells directly to the NHS. In the USA the Group sells directly to a range of hospital systems. The Group also sells through distributors in more than 40 countries in the European Union, Asia and the Americas.

### **Deltex Medical's objective**

To see the adoption of Deltex Medical's new TrueVue monitor, comprising both minimally invasive and non-invasive technologies, as the standard of care in haemodynamic monitoring for all patients from new-born to adult, awake or anaesthetised, across all hospital settings globally.

For further information please go to [www.deltexmedical.com](http://www.deltexmedical.com)